New evidence suggests that CHK1 inhibitors may demonstrate considerable single-agent efficacy in cancers, especially those with specific DNA repair deficiencies, a constitutively active DDR, or with oncogene-induced replicative stress. This evidence concerns the gene CHEK1 and cancer.